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The clinical translation of new cancer theranostic has been delayed by inherent cancer’s heterogeneity. Additionally, this delay has been
enhanced by the lack of an appropriate in vitromodel, capable to produce accurate data. Nanoparticles and microfluidic devices have been used to
obtain new and more efficient strategies to tackle cancer challenges. On one hand, nanoparticles-based therapeutics can be modified to target
specific cells, and/or molecules, and/or modified with drugs, releasing them over time. On the other hand,microfluidic devices allow the exhibition
of physiologically complex systems, incorporation of controlled flow, and control of the chemical environment. Herein, we review the use of
nanoparticles and microfluidic devices to address different cancer challenges, such as detection of CTCs and biomarkers, point-of-care devices for
early diagnosis and improvement of therapies. The future perspectives of cancer challenges are also addressed herein.
© 2019 Elsevier Inc. All rights reserved.
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are estimated to increase by 70% within the next two decades.1
Within these, 90% of deaths are associated with cancer
metastasis. In contrary to other cells, tumour cells are
genomically unstable which enables them to proliferate contin-
ually, resist cell death, induce angiogenesis, and to metastasize to
distant organs through lymph and blood vessels migration,
giving rise to a second tumour.2 While tumour cells are in
circulation, they are termed circulating tumour cells (CTCs) and
they can undergo further mutations, leading to different
outcomes of the primary tumour cells,3 resulting in therapy
resistance and disease progression.4 These complex and
heterogeneous scenarios have urged scientists to study a myriad
of strategies, involving namely CTCs,5, 6 proteins7, 8 and nucleic
acids9, 10 for the development of new cancer theranostic tools.
An efficient diagnosis test would allow early detection of cancer
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treatments. Still, cancer heterogeneity has played important roles
in delaying clinical translation of such approaches, as also as the
lack of an appropriate in vitro model has postponed it, as
discussed previously.11, 12
During the last decades, our capacity to develop new
strategies for theranostic has advanced significantly. Approaches
for cancer diagnosis and treatment have become more sophis-
ticated and reliable, and high throughput processes have been
applied due to forward-thinking technologies, such as the use of
nanoparticles and microfluidic devices.13, 14
The use of nanoparticles for diagnosis has been intensively
pursued, once they can be easily modified. In this reasoning,
avidin modified nanoparticles are the most common modifica-
tion found.15 Avidin modified nanoparticles can strongly
connect with biotin modified moieties without hindering their
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cells, and/or molecules, and/or modification with drugs,
releasing them over time. For example, nano-sized particles
with core-shell structures were developed by Zhang and
colleagues16 to release daunorubicin intracellularly. When
submitted to pH around 5-6, the drug was efficiently released
in cancer cells' nuclei. In a different example, 6-mercaptopurine
was conjugated with carboxymethyl chitosan as a targeted drug
release strategy to tackle leukaemia.17 The authors successfully
observed that intracellular drug release was higher in cancer cells
than normal cells.
These nanometre size structures are very attractive due to the
capability to pass through the permeable vessels present in the
tumour and then be retained there due to the reduced lymphatic
drainage (i.e. enhanced permeation and retention (EPR) effect).-
18 Thus, nanoparticles can be used for imaging, diagnose and
therapy as described in detailed elsewhere.19–21
Nonetheless, and despite the promising future of using
nanoparticles in cancer research, they present low efficiency.
Different reasons can be pointed out to hinder its efficiency, such
as interactions with cells and the high interstitial fluid pressure.
In this sense, an appropriate model capable of mimic these
complex interactions could promote the adjustment of their
design and their translation into clinics.18, 22
In the case of microfluidic devices, the latest progress in the
field brought cancer research a step closer to the reality of what
could happen within a human body. Microfluidic devices can be
designed to exhibit structures and complex systems at physio-
logical lengths scales, to incorporate controlled fluid flow,
biosensors, and mechanical stimulus, and to control the chemical
environment.23, 24 Besides, microfluidic devices allow studying
cancer complexity at a very small scale, with a reduced amount
of reagents or biological samples (e.g. blood) and lower costs
associated.25
In light of the aforementioned, new approaches, consisting of
gathering nanoparticles and microfluidic devices, are being
proposed and generating great excitement among scientists.26, 27
This match between nanoparticles and microfluidics have been
allowing to respond to cancer challenges as pictured in Figure 1:
(i) observation of the influence of natural barriers in nanopar-
ticles transport28–31; (ii) real-time monitoring of CTCs32; and
(iii) validation of new nanoparticles before testing in in vivo
scenarios.33
Herein, the recent reports dealing with the simultaneous use
of nanoparticles and microfluidic devices to capture CTCs and
envisaging the detection of very small changes on biomarker
levels in a precise manner are overviewed. Additionally, the
development of point-of-care devices to obtain a method for
early diagnosis is discussed. Finally, the use of nanoparticles and
microfluidic devices to improve therapies are also discussed in
depth.CTCs capture platforms
The development of non-invasive methods for early cancer
diagnosis is one of the main targets that could improve survival
rates. CTCs are cells that migrate from the primary tumour intoblood circulation, homing in distant organs and initiating the
formation of metastasis. Due to this behaviour, CTCs have been
emerging as the focus in the development of new diagnostic
techniques. In fact, one can envisage the use of CTCs for timely
diagnosis; prognosis of clinical outcomes; and prediction of
therapies efficiency. Nevertheless, its low concentration in blood
circulation, as low as a few hundred cells per 1 mL of blood, has
been hampering its detection and isolation, and consequently its
use. Due to these limitations, different strategies have been
proposed to capture CTCs, as epithelial cancer biomarker
(EpCAM)-based strategies and nucleic acid-based strategies,
which will be further discussed.34–36 It is important to mention
that besides capture, CTCs can be detected by the expression of
other biomarkers, such as cytokeratins, epithelial proteins or
mesenchymal proteins,37 as discussed in section 3. Biomarker
detection platforms.
EpCAM-based strategies
Several approaches have been tested to capture CTCs, as
EpCAM-based strategies. Currently, microfluidic devices asso-
ciated with nanoparticles had shown to be more efficient to
capture CTCs than the only assay commercially available, which
is designed for CTCs of epithelial origin, CELLSEARCH®CTC
Test (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+).38
The modification of nanoparticles with anti-EpCAM antibodies
followed by its immobilization into microfluidic devices seemed
to be the starting point of these strategies as reported, for
example, by Zhao’s group.34 They described the development of
anti-EpCAM modified Titanium dioxide (TiO2) nanoparticles
immobilized into a glass substrate of a microfluidic device to
capture CTCs and allow their visualization under a microscope.
But it was the possibility to recover the cells after capture that
allowed deepening the knowledge concerning CTCs. In fact,
CTCs heterogeneity is one of the main hurdles of cancer therapy.
After release from the primary tumour, CTCs can suffer mutation
and give rise to new phenotypes. For so, the new chemotherapies
developed can lose efficiency once administered in cancer
patients.4 One possible reason for CTCs develop heterogenic
profiles is the fact that they can suffer epithelial-mesenchymal
transition. This transition can also be responsible for the loss of
the marker EpCAM, decreasing the efficiency of strategies that
rely on its presence,39, 40 like the commercially available
CELLSEARCH®CTC Test.
In this reasoning, two main approaches were followed. In the
first, cells were captured by nanoparticles, and then, taking
advantage of their electronic features, released upon electric
stimulation.41 This controlled release promoted under electric
stimulation allowed recovering intact cells and the analysis of its
gene expression (Figure 2). To validate this system, the authors
evaluated the efficiency of cells’ capture using different cellular
flow rates (Figure 2, B), different cell concentrations and
different solutions (Figure 2, C).
On the second, cells were captured by magnetic nanoparticles
upon the application of a magnetic field and release when the
magnetic field was retrieved, enabling further analysis of captured
cells.35, 42, 43 One example was the study of Mohamadi RM and
colleagues that developed a platform based on the use of magnetic
Figure 1. New and improved approaches generated by the merge of microfluidic devices with nanoparticles (NP) to answer the cancer challenges. (i)
Observation of the influence of natural barriers in NP transport, such as tumour microenvironment and cut-off-pore size; (ii) Provide real-time monitoring of
cancer cells, such as CTCs migration during intravasation process; and (iii) Validation of new NP before testing in in vivo scenarios such as tag modified NP for
the capture of CTCs.
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EpCAM expressed (Figure 3).44 Additionally, they also evaluated
the EpCAMexpression by subjecting cells to different flows inside
the microfluidic device (Figure 3, A), separating the different
CTCs phenotypes. This method showed higher efficiency than the
CELLSEARCH® CTC Test and allowed the visualization and
selective recovery of cells. Noteworthy, more recently, the same
group published other studies where they showed that cells withlow EpCAM expression were related with disease progression
since they presented higher collagen uptake and higher metabolic
activity, for so, a more invasive behaviour, than cells with higher
EpCAM expression (Figure 3, B).45 As well, they showed that
patients were less responsive to therapy presented low EpCAM
expression and high levels of cancer biomarkers, such as androgen
receptor variant 7 (ARV7) and the mesenchymal marker, N-
cadherin.46
Figure 2. New platform to capture CTCs. (a) Scheme of an electroactive platform capable of capture CTCs and release them upon an induced switch.
(b) Efficiency of cell capture at different cell flow rates; and (c) different cell concentrations and solutions.41 Copyright © 2014, American Chemical Society.
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magnetic approaches, some issues still need to be addressed,
such as nanoparticle aggregation, and consequently, cell
aggregation. To address this limitation, the group of Zhang
JXJ developed a new approach with a higher magnetic force
based on a micromagnetic-integrated microfluidic system.47 The
micromagnetic film was patterned into a microchannel where
cells tagged with anti-EpCAM magnetic nanoparticles were
efficiently trapped, accomplishing a single-cell resolution.
Nucleic acid-based strategies
Nucleic acid-based strategies have emerged as more efficient
than EpCAM based approaches to capture CTCs since it has
been shown that CTCs can lose EpCAM expression. For
example, the use of DNA probes allowed the detection of low
amounts of CTCs in the study performed by Zhang H. and
colleagues.35 For this, they focused their attention on the
presence of carcinoembryonic antigen-related cell adhesion
molecule 5 (CEACAM5) mRNA in CTCs. Additionally, they
were able to improve the detection sensitivity by amplifying the
signal within the microfluidic device by adding horseradish
peroxidases and streptavidin to display a fluorescent signal. The
new microfluidic sensor showed that it was possible to detect as
low as one CTCs per mL of blood. In a similar approach, Sheng
W and colleagues48 developed a strategy based on a multivalent
DNA nanosphere to increase the number of captured CTCs. The
DNA nanospheres consisted of gold nanoparticles (AuNPs)
conjugated with ca. 95 DNA aptamers, which highly increased
the recognition capabilities. In fact, with this approach, the
authors were able to capture 100 CTCs per mL of blood.48 Morerecently, Song et al.49 modified AuNPs with 250 DNA probes
which improved the binding efficiency 100 times compared with
studies that used a monovalent aptamer. This approach,
presented an advantage since it allowed the release of captured
cells upon thiol exchange reaction for further studies.Biomarker detection platforms
Although there are several biomarkers associated with
different cancer stages, its quantification is still a challenge due
to the lack of proper measurement methods. Several technologies
have been a motif of study, including enzyme-linked immuno-
sorbent assay (ELISA) for protein biomarkers detection and
polymerase chain reaction (PCR) for nucleic acid detection.
However, these processes include several steps, resulting in
time-consuming methods. To overcome these issues, nanopar-
ticles and microfluidic devices have been used, allowing
biomarkers detection in both fluidic and tissue samples.
Fluid samples
Protein detection and quantification
Among the approaches tested, different nanoparticles, such as
quantum dots, gold and silver NP’s, were modified with specific
antibodies against different biomarkers known to be associated
with cancer (Figure 4). As shown in Table 1,50–65 several studies
have demonstrated different efficiencies regarding detection
ranges of single or multiple biomarker detection.
The first nanoparticles, quantum dots (QD), are very
attractive nanoparticles for biomarkers detection. This nanosize
particles (2-10 nm of diameter) present a semiconductor core that
Figure 3. The platform for magnetic separation of CTCs according to their EpCAM expression and their phenotypic profiling. (a) Scheme showing the
magnetic separation of CTCs by their EpCAM expression (MNPs – magnetic nanoparticles). (b) Phenotypic analysis of isolated cells showing collagen uptake
and metabolic activity by NAD(P)H response. Scale bar: 5 cm. Reprinted with permission from,45 Copyright © 2017 American Chemical Society.
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of excitation and a narrow emission spectrum that can be fine-
tuned by its size, and a high fluorescence and photostability
(Figure 4, A). Altogether, these features potentiate its use in
several fields as such as nanodiagnostics and imaging.66 For
example, the group of Samuel Achilefu immobilized the anti-
epidermal growth factor receptor (EGFR) antibody, known to be
associated with cancer, on the surface of QD.50 This way, they
showed to be capable to overcome the typical hurdle of the use of
fluorochromes for antibodies detection, which is the fluorescence
fade away over time. Additionally, they developed a new
strategy to immobilize the antibody without losing their binding
potential by using click-chemistry technique. With this new
strategy, they were able to detect in the range of ng/mL of EGFR
inside a microfluidic device.
In a different study, Hu M and co-workers developed a
microfluidic protein device based in a nanoprobe composed of
QD modified with anti-carcinoma embryonic antigen (CEA)
antibody using DNA as a bridge.51 The obtained results were
very promising and showed 4 times more sensitivity than QD
directly modified without the bridge of DNA. Additionally, they
showed that this approach detects as low as 50 fM.
Considering gold nanoparticles (AuNPs) and silver nanopar-
ticles (AgNPs), they also present improved features. AuNPs and
AgNPs can scatter light intensely and are brighter thanfluorophores.67, 68 Besides, they do not fade away over time, a
feature similar to QD. These features promoted their use in the
development of more accurate diagnosis tests by improving
signal detection (Figure 4, A). For example, Yan J and colleagues
have used signal amplification technology based on AuNPs and
silver to accomplish higher sensitivity.52 First, they immobilized
the carcinoma embryonic antigen (CEA) into a microfluidic
device, preserving the protein configuration, and used a
monoclonal antibody to detect the protein. Then, AuNPs
conjugated with secondary antibody were used to recognize
the monoclonal antibody. Finally, a silver coating was added to
enhance the signal. The results showed a tumour protein chip
with the capacity to detect a wide range of concentrations
between 5 and 50,000 ng/mL, with a limit of detection of less
than 1 pM, which is twice the sensitivity of fluorescent-based
assays. Moreover, they showed that it was possible to observe
the results using a magnifying glass. This interesting improve-
ment demonstrated its feasibility as a point-of-care device. In a
more recent work, Giuffrida and colleagues used the AuNPs for
signal enhancement. For that, they modified the AuNPs with an
aptamer to specifically recognize lysozyme.53 That enzyme is
known to be overexpressed in leukaemia patients and upon
reaction with luminol produced a chemiluminescent signal,
which was enhanced by the addition of AuNPs. This method
allowed detecting CEA concentrations as low as 44.6 fM.
Figure 4. Schematic representation of the use of NP for biomarkers detection. (a) NP can provide an optical signal allowing the detection of biomarkers with
no fading of the signal. Additionally, the addition of AgNP promote the enhancement of the optical signal; (b) NP can enhance the signal due to their
conductivity properties allowing an electrochemical detection; (c) the mass of NP can be detected by a piezoelectric mass sensor enhancing the signal obtained;
(d) NP conjugated with Ab against different protein provide multiple detection by optical signal; (e) The addition of high amounts of HRP and QD allows the
enhancement of the signal; (f) The addition of multicolour QD conjugated with Ab against different proteins also allows the enhancement of the signal.
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AuNPs can also be used due to their high conductivity
properties (Figure 4, B) as done by the group of Julio Raba
and the group of Sundaram Gunasekarana to detect biomarkers
electrochemically.54–56 The first group developed a strategy
based on the use of AgNPs to detect EpCAM molecules.54, 55
They used horseradish peroxidase (HRP)-conjugated with a
secondary antibody to trap the EpCAM molecule and upon
reaction with its enzymatic substrate produced an electric
signal proportional to the amount of protein detected. With this
strategy, they were able to detect 0.8 pg/mL. In the case of the
second group, they developed a strategy to not only detect and
quantify proteins but also detect and quantify the cells that
presented that molecule.56 In this case, they focused on the
detection of prostate-specific membrane antigen (PSMA). For
that, they used AuNPs modified with anti-PSMA antibody
immobilized onto an indium tin oxide (ITO) electrode array. In
a further step, they added a redox probe ferricyanide/
ferrocyanide, which upon capture of cells/PSMA, produced a
differential pulse voltammetry signal that was detected using an
electrochemical workstation. Nevertheless, the limits ofdetection of this strategy (in the range of ng/mL) were high
compared with other strategies. Even so, the fact that this
technique can detect cells that present this biomarker (150 cell/
mL) makes it a promising approach as a targeted therapy.
In a very different approach, AuNPs were used to enhance the
signal through the addition of mass (Figure 4, C).57 In fact, in
this example, the detection of proteins was obtained by a guided
shear horizontal surface acoustic wave (SAW) biosensor, termed
Love wave biosensor. This sensor is a piezoelectric mass sensor,
which can detect small differences in mass on its surface, but at a
higher sensitivity than other sensors, as for example quartz
crystal microbalances. Finally, to enhance the signal, the authors
added AuNPs to this biosensing platform. This strategy consisted
of the immobilization of antibodies anti-CEA on the SAW sensor
surface, where the CEA would interact and create a difference in
mass measurement. On top of that, AuNPs modified with anti-
CEA antibodies were added to enhance the mass loading effect
and consequently enhance the signal. With this combination,
researchers produced a small device, with a high sensitivity in the
range of pg/mL, and at low cost, which makes it very attractive to
possible point-of-care strategies.
Table 1
Microfluidic devices and nanoparticles for biomarker detection in fluidic samples.
Proteins Nanoparticles Biomarker Enhance
signal
Microfluidic device Detection Ref.
Single detection
Ab1 – QD EGFR - Ab2 – PS microbeads into MF ng/mL 50
Ab1 – QD and DNA bridge CEA - Ab1 – MF fM 51
- Lysozyme Aptamer –
AuNPs
Luminol droplets into MF fM 53
- EpCAM Ab2 – HRP Ab1 – AgNPs-Cts into MF pg/mL 54
- EpCAM Ab2 – HRP Ab1 – AgNPs-PVA into MF pg/mL 55





- CEA Ab1 – AuNPs Ab1 – Love wave biosensor into MF pg/mL 57
Multiple Detection
Ab2 – QD CEA/AFP - Ab1- supermagnetic NP patterned into MF ng/mL 58
Ab1/electron rich proteins – PS
microbeads
AFP QD HRP/Ab2 – AuNPs into MF pg/mL 59
Ab2 – QD CEA/AFP - Ab1 – MF fM 60
Ab2 – Au AFP/CEA/PSA Ag NPs Ab1 – PS microbeads into MF μg/mL 61
Ab2 – QD CEA/CA125/ Her-
2/Neu
- Ab1 – agarose beads into MF ng/mL 62
Nucleic
acids
- K-Ras - DNA probe – QD – magnetic bead into MF μM 63
- K-Ras - DNA probe – QD – pillars into MF nM 64
probe – AuNPs let-7 miRNA - Probe – MF 100 un./mL 65
Ab1 – primary antibody; QD – Quantum Dots; EGFR – Epidermal growth factor receptor; Ab2 – secondary antibody; PS – polystyrene; MF – microfluidic
device; CEA – carcinoma embryonic antigen; AuNPs – gold nanoparticles; EpCAM – epithelial cell adhesion molecule; HRP – horseradish peroxidase; AgNPs
– silver nanoparticles; Cts – chitosan; PVA – polyvinyl alcohol; PSMA – prostate specific membrane antigen; N-AuNPs – N-cysteamine capped gold
nanoparticles; ITO – indium tin oxide; Love – guided shear horizontal surface acoustic wave biosensor; AFP – α-fetoprotein; NP – nanoparticles; Au – gold;
PSA – prostate specific antigen; CA125 – cancer antigen 125; Her-2/Neu – Human Epidermal growth factor Receptor 2; K-Ras – Kirsten rat sarcoma viral
oncogene; let-7 – lethal-7; miRNAs – microRNA.
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single biomarker detection strategies for the development of new
diagnostic tools, the detection of several biomarkers have been
playing an important role in the achievement of more reliable
diagnostic tools (Figure 4,D). For example, Yu X and colleagues
developed a microfluidic with patterned super magnetic
nanoparticles and QD to detect simultaneously two molecules,
CEA and AFP.58 The super magnetic nanoparticles were
modified with dedicated antibodies to capture the biomarkers,
while the QD were used for fluorescence display, allowing the
quantification of biomarkers' concentration. The method allowed
the detection of CEA and AFP in the range of ng/mL, which was
higher than the efficiency obtained with single protein detection.
For so, scientists have pursued other approaches to increase the
sensitivity, which were based on the addition of high amounts of
horseradish peroxidase that allowed the bonding of high amounts
of QD, or just in the modification of QD for signal enhancement
(Figure 4, E and F, respectively). In the first case, the addition of
horseradish peroxidases, Zhu group, showed to increase the
detection limit 500 times when compared with traditional
methods, and 50 times when compared with microfluidic devicebased methods, detecting in the range of previous study i.e. pg/
mL.59 In the second case, the modification of QD, Hu et al.60
showed that by modifying them with secondary antibodies it was
possible to obtain a multicolour fluorescent signal amplifier
probe, achieving a detection limit similar to single protein
detection methods. The results showed that the modified QD
improved the detection limit of a mixture of CEA and AFP to as
low as 250 fM. Noteworthy, this value corresponds up to four
times higher sensitivity when compared with organic dyes.
Ko et al.61 and Jokerst et al.62 had pursued as well the
development of a more trustworthy test by increasing the number
of biomarkers simultaneously detected. Despite their work not
being as recent as the works presented here, nor as sensitive, it is
worth mentioning. Their work was one of the first works
involving the detection of several biomarkers simultaneously.
The study of Ko et al.61 reported an electro-immunosensing
structure to detect simultaneously three cancer biomarkers (α-
fetoprotein (AFP), CEA and PSA), in real-time. For that, they
immobilized polystyrene microbeads modified with antibodies
against the biomarkers into a microfluidic device. Then, the
authors used a coating of gold conjugated with a second antibody
Figure 5. QD based microfluidic device used to quantify the expression of proteins of tissue samples. (a) Example of a microfluidic device to quantify the
expression of proteins at a single-cell level. The microfluidic device (left) is placed on the cell-block section (center), then, upon immunoreactions, the
microfluidic device is detached from the cell-block section (right). (b) Analysis of eight different proteins using the microfluidic immunostaining system. (c)
Magnified images of detected areas, as labelled in B.72 Copyright © 2014, Royal Society of Chemistry.
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enhance the electrical signal. The results demonstrated the
detection in the range of μg/mL. Concerning the second study,
Jokerst et al.62 integrated QD labelled with antibodies, for CEA,
CA125 and Human Epidermal growth factor Receptor 2 (Her-2/
Neu) detection, and agarose beads, for antigen capture, into a
microfluidic device. With this approach, the authors were
capable to detect concentrations two times lower in comparison
with ELISA assays, which were higher compared with new
advances discussed above.
Nucleic acids detection
Since 1977, nucleic acids present in circulation have been
reported in cancer patients. Additionally, it was observed
different amounts of nucleic acids according to the stage of
cancer or treatment administered.69 Later on, the presence of
nucleic acids was correlated with the malignancy of cancer.70
However, it was only in 1994 that mutated molecules that lead to
countless genetic and epigenetic studies to detect anomalies in
cancer patients were reported.71 After this, nucleic acids began to
be studied as a diagnosis approach, similar to what happens in
protein detection. For this, QD have been used instead of
conventional fluorophores due to its optical properties as
happened for protein detection. Nevertheless, the sensitivity
values obtained for nucleic acids-based biomarkers are still very
high as compared with protein-based biomarkers detection
(Table 1). For example, in the work of Noh HN and Kim JS,
they have shown that it was possible to detect μM of oncogene,
K-Ras, through hybridization with a DNA probe coupled to the
QD.63 The QD were linked to a magnetic bead for support inside
of a microfluidic device. Upon interaction with target DNA, the
fluorescence of QD was quenched by an intercalating dye. Thisway they obtained a rapid and efficient way to detect, by
fluorescence quenching, in a few minutes in a microfluidic
device. More recently, the same group continued its studies
concerning the detection of K-Ras through quenching QD
fluorescence.64 However, this time the QD were not immobi-
lized through magnetic beads. The author’s produced pillars
inside the microfluidic device aiming to trap the QD.
Additionally, they developed a microfluidic chip with two
microchannels, enabling the simultaneous detection of the N-Ras
gene and its three nucleotides substituted mutated gene.
Interestingly, the results showed that they were able to lower
the concentration of DNA to 5 nM and even so, discriminate both
genes.
Other nucleic acids widely studied are the microRNAs
(miRNAs). The miRNAs, a highly conserved noncoding 22
nucleotides that can control gene expression, are involved in cancer
progression which makes them attractive as cancer biomarkers.
Nevertheless, nowadays they are detected through immunofluo-
rescent basedmultiple steps protocols that are too time-consuming.
To overcome this, nanoparticles have been used, improving not
only the reaction time but also the sensitivity, as shown by Roy S
and colleagues.65 They developed a device for lethal 7 (let-7)
miRNA detection without any labelling and amplification steps. In
this sense, they used a microfluidic device for probe immobiliza-
tion, which hybridizes with the entire length of target miRNA.
Then, the unhybridized probes were removed and a signalling
probewithAuNPswas allowed to interact with the remains probes.
These interactions gave a direct quantification of the number of
miRNA detected through differential interference contrast micros-
copy. This technique allowed the detection of just a few hundred
copies of miRNA present in microliters of sample and the
discrimination of other miRNA that differ only in few nucleotides.
Figure 6. Portable point-of-care was capable to detect, quick and easily, specific biomarkers. Scheme of a portable point-of-care showing (a) the unfolded
form, and (b) the fluorescent and label-free detection approaches. (c) Image of the portable point-of-care before and after assembly. Scale bar: 2 cm. (d)
Fluorescent intensity of the detection reservoir of the portable point-of-care as a function of CEA concentration (CCEA). (e) Fluorescent intensity of the
detection reservoir of the portable point-of-care as a function of AFP concentration (CAFP),86 Copyright © 2016, American Chemical Society.
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Besides fluids, tissues from cancer patients can also be
analysed (Figure 5). The molecular profiling of cancer cells can
give priceless information to personalize therapeutics. Sensitive
quantification methods capable to detect multiple molecules at a
single cell level can boost precise cancer diagnosis, as
demonstrated by Kwon S and colleagues.72 They used a QD
based microfluidic device to quantify the expression of proteins
at a single cell level through immunochemical assays and using a
control protein, β-actin, as an internal reference. For that, they
inserted a microfluidic device on top of tissue samples and
injected QD labelled with antibodies as depicted in Figure 5, A.
After, fluorescence intensity was measured and normalized with
the internal reference. This method allowed the determination of
the expression of eight different proteins in the same sample
(epidermal growth factor receptor 2 (HER2), Ki-67, Estrogen
receptor (ER), progesterone receptor (PR), mammalian target of
rapamycin (mTOR), transforming growth factor-alpha (TGF-α),
betacellulin (BTC) and HER3) (Figure 5, B and C). In a different
approach to detect and quantify multiple biomarkers, the group
of Park JK developed a method also based on QD. This time they
used cytokeratin as protein reference, which allowed not only to
normalize the values but also to remove the autofluorescence.73
They used breast cancer tissue' sections, to compare with
conventional scoring methods and labelled cytokeratin, to detect
cancer area. First, they aligned a microfluidic chip on top of the
cancer tissue samples. Then, they used QD with antibodies todetect and quantify three different biomarkers, ER, PR, and
HER2, into each respective microchannel. That technique
correlates with conventional methods and provides accurate
measurements. Besides the obvious advantage of allowing the
determination of different proteins simultaneously, these
methods hold great promise for the detection of small differences
between patients. In this sense, it would allow obtaining a more
accurate diagnosis and distinguish between different outcomes,
resulting in the administration of more personalized therapies.Portable point-of-care devices
The development of portable point-of-care devices is
important for the detection of specific biomarkers on-demand,
and quickly and easily, supporting clinical decisions (Figure 6).
Most of the portable point-of-care devices developed were
microfluidic paper-based devices established for electrochemical
signals detection.74, 75 Paper has several advantages, such as do
not involve any external devices for fluidic transportation, since
it occurs via capillary action; involves small volumes; is easy to
transport and store, and they are disposable. With these in mind,
Wang et al.76 developed a three-dimensional microfluidic paper-
based device, utilizing biocatalysts. For that, they patterned a
layer of AuNPs on the surface of the paper with capture
antibodies for CEA. Then, a glucose–air enzymatic biofuel cell
was used to self-power the device. This way, the authors were
capable to quantify the bioelectrocatalytic activity caused by the
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The results showed to be proportional to the amount of CEA
capture with a wide linear range and low detection limit of pg/
mL. Recently, Bahavarnia et al.77 developed a more sensitive
paper-based platform for the electrochemical detection CA 125
reaching values as low as 0.78 U/mL in human plasma samples.
Wu Y and colleagues also pursued a microfluidic paper-based
approach to detect multiple biomarkers (AFP, CEA, CA125 and
carbohydrate antigen 153 (CA153)).78 The developed analytical
device used a graphene layer and a co-immobilization of HRP
and antibody on silica nanoparticles, for detection and
amplification of electrochemical signals. This way, they were
capable to achieve a limit in the range of pg/mL. More recently,
Wang et al.75 developed a paper-based sensor for the detection of
CEA and neuron-specific enolase (NSE) based on the electro-
chemical features of AuNPs and Prussian Blue with similar
detection limits.
Interestingly, Fan et al.79 studied the development of a point-
of-care device for on-site detection through an electrochemical
detector and an Android smartphone. First, amino-functional
graphene (NH2-G) was modified with thionine (Thi) and with
AuNPs, to amplify the signal and provide conductivity. Upon
reaction of capture NSE with AuNPs, an electrochemical
detector measured the differential pulse voltammetry, which
was then, visualized by the Android's smartphone. This strategy
was capable of identify pg/mL of NSE, and together with its low
cost of production makes this a very competitive approach for
point-of-care devices.
In a different approach, more user-friendly point-of-care
devices were developed based on colorimetric detection.80–84
For example, Hu SW and colleagues80 developed a hydrophilic
device where droplets with magnetic nanoparticles modified
with antibodies specific for CEA were obtained. To detect the
biomarker, the authors used horseradish peroxidase modified
with an antibody to allow a 3, 5, 3′, 5′-tetramethylbenzidine
(TMB) -based colorimetric detection. This way, they were able
to detect μg/mL of the biomarker in 2 hours, relying only on
liquid dispensation. In a different study, Wu MS and colleagues
also pursued the development of a microfluidic device for
visual quantitative detection of several biomarkers,
simultaneously.81 The microfluidic device was composed of
one channel to detect and another to sense the different
biomarkers tested (adenosine triphosphate (ATP), PSA, AFP,
and thrombin). For that, they used biorecognition elements
(aptamers or antibodies), and an electrochemical tag (thionine)
immobilized in silica nanoparticles. These silica nanoparticles
activated the electrochemiluminescence reaction when con-
nected to the biomarker, producing a visual outcome in 50
seconds. Additionally, the colour developed was directly
proportional to the concentration of biomarkers and allowed
to detect concentrations in the fM range. More recently, QD
were used to obtain a device with fluorometric determination
capacities.85 For this, the authors modified QD with different
fluorescent emission peaks to detect CEA and PSA molecules
simultaneously in the range of ng/mL.
Nevertheless, these paper-based microfluidics devices present
some problems that need to be addressed. On one hand, the
irregularity of paper hampers the production of small micro-channels, as the ones achieved with other materials. On the other
hand, its fibres are not uniformly distributed which influences the
flow profile and flow rate, resulting in low reproducibility and
increases the time of analysis. To overcome those limitations,
Gao et al.86 developed a patterned photonic nitrocellulose based
microfluidic device (Figure 6), pictured in the unfold form and
after assembly in Figures 5, A and C, respectively. First, they
placed SiO2 nanoparticles into the microchannel template and
then they filled it with the nitrocellulose. After that, they
removed the nanoparticles and end up with an organized
structure of nitrocellulose. This technique allowed the produc-
tion of microchannels with 10 μm of width and consequently the
reduction of reagents needed for the analysis. Additionally, it
allowed the detection of biomarkers through two different
approaches, fluorescent, and label-free (Figure 6, B). To validate
this new designed microfluidic device, the authors analysed CEA
(Figure 6, D) and AFP (Figure 6, E). For that, they immobilized
antibodies against these biomarkers to trap them and used
secondary antibodies, fluorescently labelled, to detect them.
Despite the evident advantages of such types of microfluidic
devices, the concentrations detected were quite high, 0.021 μg/
mL for CEA and 0.032 μg/mL for AFP.
Later on, Kadimisetty and colleagues pursued the development
of 3D-printed microfluidic devices capable of measuring several
proteins simultaneously also using electrochemiluminescent
technique.87, 88 The first designs were able to detect up to three
molecules (PSA, PSMA, and PF-4) and as low as 300-500 fg/mL
in less than 1h (≈ 35 min).87 But in the last studies the authors
added an automated micro-pump integrated within the device,
enabling the detection of eight biomarker proteins (Insulin-like
growth factor 1 (IGF-1); PSA; PF-4; cluster of differentiation 14
(CD-14); Vascular endothelial growth factor D (VEGF-D); Golgi
membrane protein 1 (GOLM1); PSMA; Insulin-like growth factor-
binding protein 3 (IGFBP-3)) in human serum in less amount of
time (≈ 25 min.) with a detection limit of 85−110 fg/mL.88 The
main advantage of the system is not the efficiency, sensitivity, not
even the detection limits, but its low cost (≈$1.10) and the low
amounts of reagent needed (≈50 μL), making this device a
promising point-of-care. In fact, besides the fast and easy detection
of biomarkers on-demand, point-of-care devices should fulfil other
requisite, they should present low costs to be suited for the clinic,
including in low resources environments. NunoM. Reis evaluated
two different procedures for optical detection of PSA on a
transparent plastic microcapillary film (MCF).89 Onewas based on
carbon nanoparticles, while the other was based on AuNPs. In the
case of carbon nanoparticles, MCF was coated with a biotinylated
antibody, which then reacted with the neutravidin conjugated
carbon nanoparticle, resulting in an optical colorimetric signal. In
the case of AuNPs, the procedure was longer. First, the MCF was
coated with anti-PSA antibody, then, PSA was added and AuNPs
modifiedwith anti-PSAwere allowed to react and detect it. Finally,
to enhance PSA detection, AgNPs were added, resulting in an
optical colorimetric signal, as well. To image both procedures’
results, a flatbed scanner in transmittance mode was used.
Although, they obtained low levels of sensitivity, ng/mL, in the
case of AuNPs, and μg/mL, in the case of carbon nanoparticles, the
authors demonstrated the feasibility to produce an optical point-of-
care based on nanoparticles immunoassay labelling.
Table 2
FDA approval of new drugs during the first semester of 2019, taken from Hematology/Oncology (Cancer) Approvals & Safety Notifications.90
Drug Commercial name Company Type of cancer Molecule of interaction
Pexidartinib TURALIO™ Daiichi Sankyo Tenosynovial giant cell tumor CSF1 receptor
Darolutamide NUBEQA Bayer HealthCare Pharmaceuticals Inc. Prostate cancer Androgen-receptor
Selinexor XPOVIO Karyopharm Therapeutics Multiple myeloma CRM1
Polatuzumab vedotin-piiq POLIVY Genentech, Inc. Diffuse large B-cell lymphoma CD79b
Alpelisib PIQRAY Novartis Pharmaceuticals Corporation Breast cancer PI3K
Erdafitinib BALVERSA Janssen Pharmaceutical Companies Urothelial carcinoma FGFR
Trastuzumab and hyaluronidase-oysk Herceptin Hylecta Genentech Inc. Breast cancer HER2
CSF1- Colony Stimulating Factor 1; CRM1- Chromosome Region Maintenance 1; CD79b – Cluster of Differentiation 79b; PI3K – Phosphoinositide 3 Kinase;
FGFR – Fibroblast Growth Factor Receptor; HER2 – Human epidermal growth factor receptor 2;
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Currently, therapies have shown different efficiencies within
the same tumour, hindering its approval by the Food and Drug
Administration (FDA), and thus, its translation into clinics. In
fact, during the first semester of 2019, the FDA approved a very
limited amount of new drugs for the treatment of cancer as
summarized in Table 2.90 That types of drugs were developed
based on their interaction with specific molecules with the intent
to enhance their efficiency while decreasing any deleterious
effect for healthy cells.
One of the reasons for the scarce approval of new therapies is
the lack of an in vitro model capable to produce accurate data. In
this reasoning, microfluidic devices and nanoparticles have been
strategic for the improvement and evaluation of newly designed
pharmacotherapies in vitro.
On one hand, microfluidic devices allowed a scale-down of
traditional validation systems, such as the assessment of cell
death, lowering the amounts of reagents necessary and the time
of reaction. Cell death evaluation is usually laborious, time-
consuming and reagent consuming. For example, Zhao et al.91
studied a drug screening platform composed of a microfluidic
device and a nanoapoptotic probe. The nanoapoptotic probe
consisted of QD conjugated with Annexin-V, to detect
phosphatidylserine (a marker of apoptosis). These nanoprobes
interacted with apoptotic cells, revealing the efficacy of each
drug.
On the other hand, microfluidic devices can be designed to
offer a scenario that is as physiologically relevant as possible,
when compared with the typical in vitro two-dimensional (2D)
settings. A model that can replicate more closely the real
environment, can provide more accurate data as demonstrated by
Carvalho et al..92 In this reasoning, several studies were
performed taking in consideration this feature to obtain more
reliable data concerning therapies assessment, such as photody-
namic therapy,93, 94 concerning physiological data, such as the
nanoparticles’ transport within the tumour environment,95, 96 or
concerning the prediction of the effect of therapies during cancer
treatment, such as chemotherapy and radiotherapy.97
Furthermore, the use of microfluidic devices and nanoparti-
cles has been crucial for the study of new strategies and to
overcome some issues related with the development of efficient
therapies, such as the low targeting efficiency, and related withdrug delivery, namely the retention observed during systemic
administration (Figure 7). For example, nanoparticles can mount
up within diseased sites through passive targeting (i.e. due to
their inherent EPR effect) and damage healthy cells weakening
their therapeutic activity. To overcome these issues, it was
proposed the binding of specific ligands to nanoparticles to more
precisely target cancer cells (i.e. active targeting). One example
is the use of laminin receptors as a target for lung melanoma
metastasis by Sarfati and colleagues.98 The rational was the high
levels of laminin receptors presented by cancer cells and their
roles during invasion of host tissues, leading to the production of
ten times more metastases.99 It is described that the receptors
expressed in cancer cells interact with the laminin present on the
basement membrane. This interaction, enable the proteolytic
degradation of the matrix, and ultimately, the invasion of deeper
connective tissues.100 During this study, Sarfati and colleagues98
assessed the effectiveness of modified nanoparticles uptake by
cancer cells in vitro using a microfluidic flow-through system.
This system enables the prevention of nanoparticle precipitation
and any non-specific adsorption on cells due to the constant flow.
Additionally, the flow to which cells were submitted emulated
the flow of blood vessels, providing a more realistic environment
to the in vivo than standard 2D. Since blood vessels are one of
the major "highways" for cancer spreading and metastasis
formation, it is possible to predict the enormous advantages of
using microfluidic devices for these types of studies as shown by
Kolhar and colleagues.101 The authors studied intercellular
adhesion molecule-1 (ICAM-1) expressed by endothelial cells
and associated with aggressive cancers by facilitating their
invasion.102, 103 To screen the efficiency of the modified
nanoparticles, researchers injected them intravascularly and at
the same time into a microfluidic device.101 The effect of
nanoparticles' shape, rods or spheres, was also a motif of study,
due to their percussions on hydrodynamics. The results reported
that rod-shaped particles, with higher aspect ratio, had increased
selectivity towards endothelial cells than sphere-shaped particles.
This difference improved the specificity of the ligand present in
the surface of the nanoparticles, in vitro as well as in vivo,
certifying once more the value of the microfluidic devices as an
in vitro setting. In a different study, iron-gold (Fe–Au)
nanoparticles modified to target cancer cells underflow, and
induce cell death by magnetic hyperthermia coupled to force-
induced signalling pathway hyperactivation were investigated.-
104 In this case, the target selected was a receptor tyrosine kinase
Figure 7. (a) Target of cells using heregulin (HRG)–nanoparticles. Confocal images showing targeted (NR-HRG) and non-targeted (Control) cells (ErbB2
receptors – green and nuclei – blue). Stars indicate examples of ErbB2 receptor clusters. Scale bars: 10 μm.104 Copyright © 2014WILEY-VCHVerlag GmbH&
Co. KGaA, Weinheim; (b) Fluorescent microscopy images showing the adhesion strength of modified nanoparticles (SiO2-M75) and control (SiO2) to cells
under fluid flow conditions. Scale bar: 100 μm.109 Copyright © The Royal Society of Chemistry 2013.
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receptors are described to be overexpressed in several types of
solid tumour.105 The results showed that nanoparticles not only
favourably target cancer cells but also induced cell death when
stimulated.
Also, the use of microfluidic devices has allowed the
improvement of other therapies, as photothermal therapies
promoted by plasmonic materials. These materials can produce
heat upon near-infrared light exposure. This phenomenon is called
surface plasmon resonance (SPR) and occurs due to rapid
oscillations in the material's electrons. The use of such
characteristics, associated with the fact that those same nanopar-
ticles can be functionalized with drugs of interest, could improve
drug delivery efficacy. Nevertheless, tumours have shown to have
the capacity to adapt to several adversities, namely thermotoler-
ance, which can be assigned to heat-shock factor-1 (HSF1). This
molecule protects cells from damage induced by high temperatures
and is activated in tumours.106, 107 The capability to test in vitro
cellular adaptations and understand the pathways behind it can
improve largely drug delivery approaches. In this sense, and to
understand the repercussion of the activity of this molecule in drug
delivery, Bagley and colleagues used a microfluidic device to
mimic tumor vasculature.108 For that, the authors developed a
monolayer of endothelial cells encapsulated in collagen type I
inside microchannels of the microfluidic device. Then, they
observed the effects of local heating induced by AuNPs on the
developed endothelial model. The results showed that continuous
exposure to heat, in fact, hindered the transport and it is associated
with HSF1.
Concerning the use of nanoparticles, other improvements
must be considered to overcome additional obstacles. Nanopar-
ticles are subjected to different barriers once inside the human
body. For example, the blood flow, the interactions with the
endothelium and the interactions with other healthy cells, which
usually are not consider. Moreover, the complex environmentaround the tumour, as the high interstitial fluid pressure and the
dense extracellular matrix, has also hindered the transport,
preventing the necessary amounts of nanoparticles to reach target
places. One of the first barriers is endothelium. It was with this in
mind that Chen et al.96 developed a model to test new drugs by
using a microfluidic chip with the capacity to mimicry the
endothelial wall and the tumour microenvironment. Within this
setting, the authors observed that, although the drug delivery
systems assessed, went through the endothelial wall of two
different breast cancer types' scenarios, they showed different
cancers' microenvironment penetration rates. Another barrier is
the interaction with cells. For so, Tokárová et al.109 reported the
use of a microfluidic device to study adhesion strength of
nanoparticles to cells (Figure 7, B). Different approaches have
been pursued to obtain an effective and strong adhesion to
tumour cells, which ultimately, would improve the development
of new chemotherapies. During this work, silica nanoparticles
were modified with an antibody specific for the transmembrane
protein, carbonic anhydrase IX (SiO2-M75), which is express in
tumour cells under hypoxic conditions. The results showed that
the nanoparticles were small enough to pass through the large
porous typical of new tumour vasculature, which is not observed
in healthy tissue, and persisted adhered under flow rates similar
to the ones observed in the tumour vasculature. Additionally, the
results demonstrated that the strength of nanoparticles adhered to
cancer cells was higher than non-specific modified nanoparticles.
More recently, Jarvis et al.29 studied another barrier, the
infiltration of nanoparticles used for drug delivery from the
blood vessels until the tumour mass and throughout a tumour
mass. In this interesting evaluation, they mimic blood vessels by
culturing endothelial cells along an outer microchannel, and the
tumour mass by culturing breast cancer cells within a Matrigel
matrix inside an inner chamber. Then, this co-culture micro-
fluidic device was perfused with camptothecin nanocrystals
modified with folic acid, a target for breast cancer cells. The
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able to superficial penetrate the tumour mass, they dissolve, and
this way, they can infiltrate further, inducing tumour cells' death
along with the mass.Conclusions and future directions
Traditional cancer diagnosis tools are still limited in their
sensitivity and specificity. Therefore, new techniques have been
pursued, such as the detection of CTCs and biomarkers.
On one hand, there is an incredible interest in the detection of
CTCs due to their evident association with cancer progression.
Several approaches concerning the use of EpCAM for CTCs
detection were studied and even reach the clinic. But the addition
of nanoparticles and microfluidic devices allowed to go further,
enabling the capture and visualization of cells out of small
amounts, and more efficiently than the commercially available.
Even so, researchers have been showing that EpCAM expression
may decrease during epithelial-mesenchymal transition or by
mutation of the cells, which compromise the efficiency of those
approaches. For so, new alternatives have been studied as the use
of nucleic acid-based strategies to detect CTCs. These strategies
showed to be more efficient and more sensitive than EpCAM
based strategies. Furthermore, the use of nanoparticles and
microfluidic devices showed to improve detection sensitivity as
compared with assays performed in traditional microtubes.
On the other hand, the detection of biomarkers has sparkle
cancer field due to its association with different cancer stages.
The detection of single biomarkers within fluid samples, like
EGFR, CEA, PSA, and K-Ras, or its simultaneous detection,
have been studied to get a more accurate and reliable diagnostic
tool. Even so, it is important to mention that higher sensitivity
has been obtained for protein-based biomarkers detection as
compared with nucleic acid-based biomarkers detection. Several
approaches were tested to improve sensitivity and selectivity, as
the use of signal amplification by using silver nanoparticles, gold
nanoparticles, quantum dots, horseradish peroxidase or even a
combination of them. The result of such approaches allowed the
improvement of the limit of detection as compared with
traditional methods. Additionally, it was also studied the
presence of biomarkers directly from tissues from cancer patients
since it can give important information for a more personalized
therapy.
Despite the impressive progress made thus far that allowed to
detect very small changes of biomarkers levels in a precise
manner, the developed strategies have struggled to be approved
by regulatory agencies (e.g. FDA) and to be used in the clinics.
This can be justified by the lack of information regarding the
safety of these strategies. Therefore, it is imperative to deepen the
studies in a way they answer the main question raised by the
FDA "is the product safe and effective?”, to fasten new strategies
translation. A different drawback is the cost associated with
many strategies developed. Nowadays, the existing ones are
expensive and the trend points to an increase in these prices.
Furthermore, since the fabrication of microfluidic devices is
mostly obtained by casting-based moulding approaches, it is
difficult to fully automatize the entire process, resulting in anexpensive and time-consuming process. Unfortunately, devel-
oping countries are the most affected. If the strategies developed
to follow the same trend, they will not be accessible at all. For so,
a new concern has arisen, i.e. the development of affordable
point-of-care devices that ultimately would support clinical
decisions are in great need. In this reasoning, new low-cost
platforms have been developed. Most of them do not need any
label to detect biomarkers, which minimizes the complexity and
the cost associated with diagnostics. Additionally, these devices
are easy to transport and store and enable fast and easy detection
of specific biomarkers. Amongst the studied devices, paper-
based devices have been showing to be a promising tool to
achieve this goal. They do not need external devices to promote
fluid transportation, are easily transportable and storable, and are
easily disposable. Nevertheless, some drawbacks as the
irregularity of paper and the uneven fibres still need to be
surpassed. Additionally, a different strategy has been pursued,
the use of 3D printing to develop cost-effective microfluidic
devices. This approach allows obtaining complex structures with
desired features within a small amount of time and with reduced
cost. The designed microfluidic device can be obtained in a
single step, layer-by-layer, from a computer-aided drawing file.
Moreover, 3D printing techniques guarantee a more reproducible
device as compared with traditional methods.
Although technology has developed towards new efficient
and precise strategies, there are still many drawbacks to
overcome, and finally, reach the clinic. Overall, the combination
of nanoparticle and microfluidic research fields will enable us to
engineer a new generation of point-of-care systems for early
diagnosis that will certainly allow improving cancer treatment
(personalized and cost-effective manner), in a near future.Acknowledgements
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